Neurology®

The most widely read and highly cited peer-reviewed neurology journal
The Official Journal of the American Academy of Neurology

Neurology Publish Ahead of Print
DOI: 10.1212/WNL.00000000000013181

Pearls & Oy-sters: Cerebral Abscess Secondary to Pulmonary Arteriovenous Malformation in Hereditary Hemorrhagic Telangiectasia

Author(s):

Jodie I. Roberts, MD, MSc¹; Kristine Woodward, MD, MSc²; Adam Kirton, MD, MSc¹⁻⁴; Michael J. Esser, MD, PhD²⁻⁴

Neurology® Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes.

Corresponding Author:

Jodie I. Roberts
jirobert@ucalgary.ca

Affiliation Information for All Authors: 1. Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; 2. Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; 3. Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada; 4. Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada

Contributions:

Jodie I. Roberts: Drafting/revision of the manuscript for content, including medical writing for content
Kristine Woodward: Drafting/revision of the manuscript for content, including medical writing for content
Adam Kirton: Drafting/revision of the manuscript for content, including medical writing for content
Michael J. Esser: Drafting/revision of the manuscript for content, including medical writing for content

Number of characters in title: 126

Abstract Word count: 237

Word count of main text: 1500

References: 15

Figures: 1

Tables: 1

Supplemental: Patient consent-to-disclose form

Search Terms: [14] All Clinical Neurology, [136] Abscess, [227] All Pediatric

Study Funding: The authors report no targeted funding

Disclosures: The authors report no disclosures relevant to the manuscript.

Abstract:

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal-dominant condition which is linked to a myriad of neurological complications arising from vascular malformations of the brain, spinal cord, and lungs. Our case describes a previously healthy 3-year-old male who presented to hospital with fever of unknown origin and was found to have a brain abscess stemming from a pulmonary arteriovenous malformation (PAVM). This etiology was identified after a period of diagnostic delay; the medical team was suspicious for a proximal embolic source due to the presence of multiple tiny infarcts seen on MRI brain, but transthoracic echocardiogram and head and neck angiogram were unremarkable. Fortunately, an enhanced CT chest was performed, identifying a moderately-sized PAVM. PAVMs are associated with intracranial abscesses due to shunting and loss of the normal filtering effects of the lung capillary bed. Impaired pulmonary filtration can permit paradoxical thromboemboli and septic microemboli to enter systemic circulation, predisposing patients with PAVMs to cerebral abscess and ischemic stroke. Screening for PAVMs with contrast enhanced echocardiogram or enhanced CT chest may be considered in patients with cryptogenic brain abscess or recurrent embolic stroke of unknown origin. PAVMs are often associated with hereditary hemorrhagic telangiectasia (HHT). As many features of HHT have delayed clinical manifestation, genetic testing for HHT should be considered in patients with PAVM, even in the absence of other clinical features. In our case, genetic testing returned positive, confirming a new diagnosis of HHT type 1.

Pearls:

- Pulmonary arteriovenous malformations (PAVMs) produce a continuous right-to-left shunt which allows a proportion of systemic venous blood to bypass pulmonary bed filtration.
- Impaired pulmonary filtration can permit paradoxical thromboemboli and septic microemboli to enter systemic circulation, predisposing patients with PAVM to cerebral abscess and ischemic stroke.
- PAVMs are often associated with hereditary hemorrhagic telangiectasia (HHT).

Oy-sters:

- Screening for PAVM with contrast echocardiogram or CT chest may be considered in patients with cryptogenic brain abscess or recurrent embolic stroke of unknown origin.
- Many features of HHT have delayed clinical manifestation, and genetic testing for HHT should be considered in patients with PAVM, even in the absence of a history of epistaxis or telangiectasias.

Case Report:

A 3-year-old male was hospitalized with a four-week history of fever of unknown origin. He was previously healthy and developmentally normal. At onset, he had a high-grade fever (T-max $\geq 39^{\circ}\text{C}$) associated with persistent emesis and headache. He first presented to hospital after 4 days of illness and received 3 doses of intravenous antibiotics, but was discharged with a diagnosis of viral gastroenteritis after blood and urine cultures returned negative and fever resolved. He was re-admitted 3 days later due to recurrent fever. While complete blood counts

were normal, he had mild elevations in erythrocyte sedimentation rate (14 mm/hr (normal ≤ 10)) and c-reactive protein (19.2 mg/L (normal ≤ 8.0)). Cerebrospinal fluid (CSF) was notable for 9 white blood cells (78% lymphocytes) with normal protein (0.26 g/L) and glucose (3.5 mmol/L). He received 3 days of antibacterial and antiviral therapy which was discontinued after CSF viral panel and culture returned negative. He was discharged home with a diagnosis of fever of unknown origin. He was re-admitted one week later, and the possibility of an atypical pneumonia or sarcoidosis was queried due to intermittent oxygen requirements and a questionable focal opacity in the left lower lobe on chest x-ray (Figure 1A). Repeat respiratory panels, blood and urine cultures were negative. He was transferred to our tertiary care centre for further investigation.

Ophthalmologic assessment was performed for newly onset ocular misalignment. Examination was limited by cooperation. Fundoscopic examination revealed blunting of the left optic disc margin. Visual acuity and confrontational fields could not be assessed. Pupils were equal and reactive. Ocular ductions appeared full, but an intermittent comitant right esotropia was seen. Enhanced MRI brain was subsequently ordered which revealed a large left parietooccipital abscess as well as tiny infarcts in multiple vascular territories (Figure 1C-F). As there were no abnormalities in the brainstem or significant mass effect, his acute onset strabismus was hypothesized to represent an adaptation to an undetected homonymous hemianopia from parietooccipital brain abscess.

Aspirate from the abscess cultured *S. anginosus* (a subgroup of viridans streptococci) which was susceptible to treatment with intravenous ceftriaxone. The source of infection was unclear; dentition was normal and sinuses were clear on MRI. Given multiple tiny infarcts seen on brain MRI, the possibility of a proximal embolic source was considered. Transthoracic

echocardiogram with bubble study did not reveal a source of embolus or shunt. Neck ultrasound and cerebral angiogram were additionally unremarkable. An enhanced chest CT was ordered to investigate for a pulmonary shunt; this demonstrated a moderately-sized left lower lobe pulmonary arteriovenous malformation (PAVM), which corresponded to the focal opacity previously seen on chest x-ray (Figure 1B). An additional focus of ground-glass change was seen at the right lung base which raised suspicion for a second tiny PAVM (not shown). The source of cerebral abscess was concluded to be paradoxical emboli in the setting of PAVM-associated right-to-left shunt and loss of the pulmonary capillary bed filtering. He underwent successful catheter embolization of his left lower lobe PAVM and had resolution of his ocular misalignment.

Although there was no known history of affected relatives, epistaxis, telangiectasias or gastrointestinal bleeding, a diagnosis of hereditary hemorrhagic telangiectasia (HHT) was considered. Genetic testing confirmed a c.991G>A heterozygous pathogenic variant in *ENG* consistent with a diagnosis of HHT type 1. Surveillance imaging did not identify any AVMs of the brain or liver. He was referred to a specialized HHT centre for ongoing management.

Discussion:

Hereditary hemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an autosomal-dominant multisystem vascular disease with a prevalence of 1:5,000 to 1:10,000 which is associated with a myriad of primary and secondary neurological complications.^{1,2} Pathogenic gene variants in *ENG* (HHT type 1), *ACVRL1* (HHT type 2) and *SMAD4* (juvenile polyposis overlap syndrome) disrupt transforming growth factor- β (TGF- β) signaling pathways on vascular endothelial cells, leading to vascular fragility and malformations.³ A diagnosis of HHT can be made through identification of a causative mutation or by application of the Curaçao

criteria (Table 1).⁴ The four Curaçao criteria include: (1) spontaneous and recurrent epistaxis; (2) multiple mucocutaneous telangiectasis of the lips, oral cavity, fingers or nose; (3) visceral lesions (gastrointestinal telangiectasis or pulmonary/hepatic/cerebral/spinal AVMs); and (4) a first-degree relative with HHT.⁵ HHT is considered ‘possible or suspected’ with two criteria present and ‘definite’ with three or more positive criteria.⁵

HHT patients experience primary neurological complications secondary to vascular malformations in the brain or spinal cord. Although cerebral vascular malformations (CAVMs) are found in nearly a quarter of patients with HHT,⁶ spinal AVMs are uncommon and not routinely screened for.⁷ Although natural history varies by AVM type, the overall annual hemorrhage rate for unruptured CAVMs is 2.2% (95% CI 1.7% - 2.7%).⁸ Symptomatic CAVMs may also present with seizure or headache.⁹ Expert guidelines recommend screening for brain vascular malformations with brain MRI in all patients with possible or definite HHT.⁴ Surgical management is considered on a case-by-case basis.⁹

Secondary neurologic complications arising from pulmonary arteriovenous malformations (PAVMs) are a much more frequent cause of neurologic sequela in HHT. PAVMs are abnormal blood vessels found in approximately 50 percent of HHT patients which directly connect pulmonary arteries and veins, producing a continuous right-to-left shunt and allowing for a proportion of systemic venous blood to bypass pulmonary bed filtration and gas exchange.¹⁰ Partial loss of pulmonary capillary filtering impairs systemic prevention of paradoxical emboli, resulting in an increased risk of ischemic stroke; one UK study reported ischemic stroke in 12 percent of persons with a PAVM.¹⁰

Although rare in the general population, the odds of developing a cerebral abscess are substantially elevated (OR 30.0, 95% CI 3.1-288) in patients with HHT,¹ with 6 percent of

individuals with a PAVM experiencing a cerebral abscess.¹⁰ The presence of a right-to-left shunt allows septic microemboli to bypass the filtering effect of the pulmonary capillaries, yielding a direct path to the cerebral circulation. The possibility of PAVM should be considered in patients with cerebral abscess that do not have predisposing risk factors such as immunocompromised state, history of head trauma or neurosurgery, dental infection, ENT infection or congenital heart disease.¹¹

In our case, the finding of a cryptogenic brain abscess did not immediately raise suspicion for the possibility of a PAVM or HHT. Missed or delayed diagnoses of HHT are common, with an average time lag between development of HHT manifestations and diagnosis nearing three decades.² Although this reflects lack of disease awareness, another culprit is delayed clinical expression of common HHT manifestations. While nearly all patients (>90%) with HHT eventually develop recurrent epistaxis, the mean age of onset is 12 years.¹² Similarly, mucocutaneous telangiectasias do not occur until after puberty, and may not occur until adulthood.¹³ Importantly, as nearly all PAVMs are due to HHT, all patients with PAVMs should be screened for HHT, even in the absence of other clinical manifestations.¹⁴

Although our patient's PAVM was found using CT imaging of the chest, recommended first-line screening for PAVMs in patients with possible or confirmed HHT is with transthoracic contrast echocardiography.⁴ Due to the risk of new PAVM development, enlargement of existing PAVMs or progression of previously embolized PAVMs, pediatric-specific guidelines recommend repeating pulmonary AVM screening at 5-year intervals.⁴ In the adult setting, it is recommended that all PAVMs are treated with transcatheter embolectomy; whereas in the pediatric setting, PAVMs are only treated if they are large or associated with reduced oxygen saturation.⁴ Regardless of whether pulmonary AVMs are treated or untreated, patients should receive

antibiotic prophylaxis for procedures with risk of bacteremia (such as dental procedures), take precautions against air embolism during intravenous administration, and avoid SCUBA diving.⁴

While HHT prognosis varies by individual disease severity, overall survival is only modestly reduced, with a median age of survival of 77 years.¹ Risk of death is highest in the first 3 years after diagnosis, reflecting that most patients are diagnosed after presenting with a complication.¹ Although current interventions are largely surgical, several potential therapeutic targets have been recently identified,¹⁵ and a stage 3 clinical trial of bevacizumab, a monoclonal antibody which targets the vascular endothelial growth factor (VEGF) signaling pathway is underway (NCT 03227263).

Our case highlights the importance of screening for PAVM in patients with cryptogenic brain abscess or recurrent embolic stroke of unknown origin. Particularly in younger patients, additional clinical manifestations of HHT may not yet be apparent, and detection of a PAVM allows for appropriate management and surveillance.

Figure Caption

Figure 1. (A) Anterior-posterior chest radiograph demonstrating a subtle opacity in the left lower lobe. (B) Enhanced CT chest demonstrating a pulmonary arteriovenous malformation corresponding to the area of opacity seen on chest x-ray. (C-D) Axial brain MRI demonstrating a mature, multi-lobulated parietal-occipital abscess with associated central diffusion restriction on (C) diffusion-weighted imaging and (D) apparent diffusion coefficient maps, with substantial perilesional edema. (E) Thick, smooth ring enhancement is present on T1 post-gadolinium sequences with central hypointensity. (F) Multiple punctate foci of diffusion restriction were additionally seen, suggestive of tiny emboli.

Table 1: Summary of highlighted diagnostic and surveillance recommendations in hereditary hemorrhagic telangiectasia.

Consideration	Recommendation
Diagnostic	<ul style="list-style-type: none"> An underlying diagnosis of HHT should be considered in all patients with a PAVM¹⁴. An underlying diagnosis of HHT should be considered in patients meeting two or more Curaçao criteria⁵: <ol style="list-style-type: none"> (1) spontaneous and recurrent epistaxis; (2) multiple mucocutaneous telangiectasis of the lips, oral cavity, fingers or nose; (3) visceral lesions (gastrointestinal telangiectasis or pulmonary/hepatic/cerebral/spinal AVMs); (4) a first-degree relative with definite HHT.
Targeted Screening	<ul style="list-style-type: none"> PAVM screening should be performed at the time of HHT diagnosis (adult/pediatric patients) and repeated at 5-year intervals (pediatric patients only)⁴. All adult patients with possible or definite HHT should receive MRI screening for brain vascular malformations at the time of diagnosis⁴. Spinal arteriovenous malformations are not routinely screened for⁷.

HHT = hereditary hemorrhagic telangiectasia; PAVM = pulmonary arteriovenous malformation

References

1. Donaldson JW, McKeever TM, Hall IP, Hubbard RB, Fogarty AW. Complications and mortality in hereditary hemorrhagic telangiectasia: A population-based study. *Neurology*. 2015;84:1886–1893.
2. Pierucci P, Lenato GM, Suppressa P, et al. A long diagnostic delay in patients with Hereditary Haemorrhagic Telangiectasia: a questionnaire-based retrospective study. *Orphanet J Rare Dis*. 2012;7:33.
3. Shovlin CL, Simeoni I, Downes K, et al. Mutational and phenotypic characterization of hereditary hemorrhagic telangiectasia. *Blood*. 2020;136:1907–1918.
4. Faughnan ME, Mager JJ, Hetts SW, et al. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. *Ann Intern Med*. 2020;173:989–1001.
5. Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). *Am J Med Genet*. 2000;91:66–67.
6. Fulbright RK, Chaloupka JC, Putman CM, et al. MR of hereditary hemorrhagic telangiectasia: prevalence and spectrum of cerebrovascular malformations. *AJNR Am J Neuroradiol*. 1998;19:477–484.
7. McDonald J, Bayrak-Toydemir P, Pyeritz RE. Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis. *Genet Med Off J Am Coll Med Genet*. 2011;13:607–616.
8. Gross BA, Du R. Natural history of cerebral arteriovenous malformations: a meta-analysis. *J Neurosurg*. 2013;118:437–443.
9. Brinjikji W, Iyer VN, Sorenson T, Lanzino G. Cerebrovascular Manifestations of Hereditary Hemorrhagic Telangiectasia. *Stroke*. 2015;46:3329–3337.
10. Shovlin CL, Condliffe R, Donaldson JW, Kiely DG, Wort SJ. Pulmonary arteriovenous malformations emerge from the shadows. *Thorax*. 2017;72:1071–1073.
11. Bodilsen J, Dalager-Pedersen M, van de Beek D, Brouwer MC, Nielsen H. Incidence and mortality of brain abscess in Denmark: a nationwide population-based study. *Clin Microbiol Infect*. 2020;26:95–100.
12. AAssar OS, Friedman CM, White RI. The Natural History of Epistaxis in Hereditary Hemorrhagic Telangiectasia: The Laryngoscope. 1991;101:977–980.
13. Porteous ME, Burn J, Proctor SJ. Hereditary haemorrhagic telangiectasia: a clinical analysis. *J Med Genet*. 1992;29:527–530.

14. Shovlin CL, Condliffe R, Donaldson JW, Kiely DG, Wort SJ. British Thoracic Society Clinical Statement on Pulmonary Arteriovenous Malformations. *Thorax*. 2017;72:1154–1163.
15. Robert F, Desroches-Castan A, Bailly S, Dupuis-Girod S, Feige J-J. Future treatments for hereditary hemorrhagic telangiectasia. *Orphanet J Rare Dis*. 2020;15:4.

ACCEPTED

Neurology®

Pearls & Oy-sters: Cerebral Abscess Secondary to Pulmonary Arteriovenous Malformation in Hereditary Hemorrhagic Telangiectasia

Jodie I. Roberts, Kristine Woodward, Adam Kirton, et al.

Neurology published online December 8, 2021

DOI 10.1212/WNL.00000000000013181

This information is current as of December 8, 2021

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/early/2021/12/07/WNL.00000000000013181.full
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): Abscess http://n.neurology.org/cgi/collection/abscess All Clinical Neurology http://n.neurology.org/cgi/collection/all_clinical_neurology All Pediatric http://n.neurology.org/cgi/collection/all_pediatric
Permissions & Licensing	Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2021 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.